PharmAla Biotech ships MDMA to Mind Medicine Australia, Orygen Institute

PharmAla Biotech announced that is has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia, a charity which seeks to alleviate the suffering caused by mental illness in Australia through expanding treatment using psychedelic molecules. The contract with Mind Medicine Australia was announced in May of 2022, and is now considered complete. PharmAla remains, at this time, the only publicly traded company in the world to have successfully manufactured GMP MDMA drug product – appropriate for human use – and to have shipped that product to Australia. PharmAla is also pleased to announce that it, and its manufacturing partners, have completed shipment of its GMP LaNeo MDMA capsules to the Orygen Institute, affiliated with the University of Melbourne. This shipment represents the first of two shipments which will support a Clinical Trial registered by the Orygen Institute, with the second shipment scheduled for 2024. The contract was previously announced in a press release dated August 22, 2022.